Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

The gross carrying amount and accumulated amortization of intangible assets were comprised of the following at the end of each period:

	Successor				Predecessor
	September 30, 2022				December 31, 2021
	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortizable:
Completed technology	$	3,041.2	$	182.1	$	10,404.0	$	5,160.4
License agreements	—		—		120.1		82.1
Trademarks	—		—		77.7		26.9
Total	$	3,041.2	$	182.1	$	10,601.8	$	5,269.4
Non-Amortizable:
Trademarks	$	—			$	35.0
In-process research and development	121.3				81.0
Total	$	121.3			$	116.0

Intangible Asset Amortization Expense

Intangible asset amortization expense was as follows:

	Successor		Predecessor
	Three Months Ended September 30, 2022		Three Months Ended September 24, 2021
Amortization expense	$	136.6	$	145.3

	Successor		Predecessor
	Period from June 17, 2022 through September 30, 2022		Period from January 1, 2022  through June 16, 2022		Nine Months Ended September 24, 2021
Amortization expense	$	182.1	$	281.8	$	435.8

Schedule of Future Amortization Expense, Intangible Assets

The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows:

	Successor
Remainder of Fiscal 2022	$	136.5
Fiscal 2023	509.3
Fiscal 2024	446.1
Fiscal 2025	385.1
Fiscal 2026	337.5

Schedule of Intangible Assets and Goodwill

Intangible assets of the Successor as of the Effective Date consisted of the following:

	Carrying Amount		Amortization Method	Amortization Period (in years)	Discount Rate	Segment
Amortizable completed technology:
Acthar Gel	$	1,069.0	Sum of the years digits	13.5	14.2%	Specialty Brands
Therakos	913.8		Sum of the years digits	10.0	14.0	Specialty Brands
Amitiza	84.5		Sum of the years digits	3.0	14.0	Specialty Brands
INOmax	652.9		Sum of the years digits	9.0	14.0	Specialty Brands
StrataGraft	56.8		Straight-line	11.0	14.0	Specialty Brands
Generics	71.4		Straight-line	5.0	13.3	Specialty Generics
APAP	70.5		Straight-line	20.5	13.0	Specialty Generics
	2,918.9
Non-Amortizable in-process research and development:
Terlivaz (1)	104.8		Straight-line	7.0	15.0	Specialty Brands
Generics IPR&D	128.5		Not applicable	Not applicable	14.0	Specialty Generics
	233.3
	$	3,152.2